Febuxostat 20 mg & 40 mg Tablets (MAH: Wuhu Yangyan) developed by Huayi Pharma have been approved!
Febuxostat tablets, a xanthine oxidase inhibitor that can reduce serum uric acid concentration by inhibiting uric acid synthesis and apply to the long-term treatment of hyperuricemia in gout patients, was approved by NMPA through the professional and high-efficient technical services of Huayi.
This is the third NMPA approved product in Huayi in addition to the previous Sildenafil Citrate Tablets and Gliclazide Sustained release Tablets. We believe that, in the future, Huayi will provide more high-efficient, high-quality and cost-controllable generic drug development and manufacture services to get approval for more products.